Understanding De Risking Drug Development Using Functional Human Tissues
If you are looking for information about De Risking Drug Development Using Functional Human Tissues, you have come to the right place. Dr. Andre Ghetti, CEO of AnaBios, joins to discuss how his company helps
Key Takeaways about De Risking Drug Development Using Functional Human Tissues
- Hepatotoxicity due to
- Hebrew University researchers develop bionic chips to create cancer-fighting
- What does it take to turn complex biology into clear, client-ready insight? Meet Parisa, a PhD-trained oncology scientist
- This panel discussion was part of the 2018 Technology in Psychiatry Summit, an event sponsored by the McLean Institute forย ...
- Rare diseases affect millions of people worldwide, yet therapeutic
Detailed Analysis of De Risking Drug Development Using Functional Human Tissues
Today we welcome Brandy Wilkinson, CEO of GemPharmatech (https://en.gempharmatech.com) , and Rikki Feng, the company'sย ... On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company'sย ... C-Path's Rare & Orphan Disease Conference was 2.5-day conference held Sept. 11-13, that included patients, providers,ย ...
Looking to
We hope this detailed breakdown of De Risking Drug Development Using Functional Human Tissues was helpful.
